Effects of caffeine on anxiety and panic attacks in patients with panic disorder: A systematic review and meta-analysis
Klevebrant L, Frick A
General hospital psychiatry · 39 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Åke Wiberg Stiftelse
- Organización sin fines de lucro
- Hjärnfonden
- Gobierno
- Vetenskapsrådet
- Organización sin fines de lucro
- Kjell och Märta Beijers Stiftelse
- Organización sin fines de lucro
- Brain Foundation
- Gobierno
- Swedish Research Council
- Organización sin fines de lucro
- Kjell and Märta Beijer Foundation
- Organización sin fines de lucro
- Åke Wiberg Foundation
Según 8 financiadores declarados.
Publicación
- Publicado
- 2021-12-01 · Gen Hosp Psychiatry · vol. 74 · págs. 22–31
- Editorial
- Elsevier BV
- Citado
- 62 citas · más que el 83% de estudios similares · 1.5× el promedio de su campo
- Referencias
- 65 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Coffee research and impacts · Smoking Behavior and Cessation · Cannabis and Cannabinoid Research
- Palabras clave
- Anxiogenic, Panic, Panic disorder, Caffeine, Anxiety, Placebo, Meta-analysis, Anxiety disorder, Psychiatry, Medicine, Internal medicine, Psychology, Clinical psychology, Anxiolytic
- MeSH
- humans, caffeine, anxiety, anxiety disorders, panic disorder, adult
2 autores
- Lisa Klevebrant🇸🇪Uppsala University
- Andreas Frick🇸🇪 · autor de correspondenciaUppsala University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Caffeine has been purported to have anxiogenic and panicogenic properties, specifically salient in patients with panic disorder (PD). However, compilations of the magnitude of the effect of caffeine on anxiety and panic attacks are lacking and potential dose-response relationships have not been examined.
Objectives
In the present systematic review and meta-analysis, we aimed to examine the acute effects of placebo-controlled caffeine challenge on occurrence of panic attacks and subjective anxiety in patients with PD and healthy controls (HC), including dose-response relationships.
Methods
Systematic searches were performed in six databases. We included blinded placebo-controlled studies of acute caffeine challenge on panic attacks and/or subjective anxiety in adult patients with PD.
Results
Of the 1893 identified articles, ten met our inclusion criteria. The 9 studies investigating panic attacks included 237 patients, of which 51.1% had a panic attack following caffeine, but none after placebo. Six of these studies compared 128 patients with 115 healthy controls (HC), finding that patients (53.9%) were more vulnerable than HC (1.7%) for panic attacks following caffeine (log RR: 3.47; 95% CI 2.06-4.87). Six studies investigated subjective anxiety in 121 patients and 111 HC following caffeine, with an overall effect indicating increased sensitivity to the anxiogenic effects of caffeine in the patient group (Hedges' g = 1.02 [95% CI: 0.09-1.96]). The restricted range of caffeine employed [400-750 mg] and few studies (3) not using 480 mg prevented any meaningful analysis of a dose-response relationship.
Limitations
Of the ten studies included, only 2 reported anxiety data for the placebo condition, precluding a proper meta-analysis comparing anxiogenic effects of caffeine and placebo. The restricted dose range used prevented assessment of dose-response relationships.
Conclusions
The results confirm that caffeine at doses roughly equivalent to 5 cups of coffee induces panic attacks in a large proportion of PD patients and highly discriminates this population from healthy adults. Caffeine also increases anxiety in PD patients as well as among healthy adults at these doses although the exact relationship between caffeine-induced anxiety and panic attacks remains uncertain. The results suggest that caffeine targets important mechanisms related to the pathophysiology of PD.
Implications
Future studies should employ a wider range of caffeine doses and investigate contributions of biological and psychological mechanisms underlying the anxiogenic and panicogenic effects of caffeine. In the clinic, patients with PD should be informed about the panicogenic and anxiogenic effects of caffeine, with the caveat that little is known regarding smaller doses than 480 mg. Registration. PROSPERO (www.crd.york.ac.uk/prospero) registration number CRD42019120220.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.